|
1) Shefner JM, Cudkowicz ME, Schoenfeld D, et al. NEALS Consortium. A clinical trial of creatine in ALS. Neurology. 2004; 63: 1656-61
|
|
|
|
2) Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther. 2011; 89: 655-61
|
|
|
|
|
3) Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76
|
|
|
|
|
|
4) Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72
|
|
|
|
|
|
5) Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8: 409-12
|
|
|
|
|
|
6) Maekawa M, Yamaguchi K, Nakamura T, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011; 474: 225-9
|
|
|
|
|
|
7) Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321: 1218-21
|
|
|
|
|
|
8) Soldner F, Hockemeyer D, Beard C, et al. Parkinsonʼs disease patient-derived induced pluripotent stem cells free of viral repro-gramming factors. Cell. 2009; 136: 964-77
|
|
|
|
|
|
9) Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinsonʼs disease. Nat Rev Neurosci. 2010; 11: 791-7
|
|
|
|
|
|
10) Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011; 8: 267-80
|
|
|
|
|
|
11) Seibler P, Graziotto J, Jeong H, et al. Mito-chondrial Parkin recruitment is impaired in neu-rons derived from mutant PINK1 induced pluri-potent stem cells. J Neurosci. 2011; 31: 5970-6
|
|
|
|
|
|
12) Boulting GL, Kiskinis E, Croft GF, et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol. 2011; 29: 279-86
|
|
|
|
|
|
13) Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009; 457: 277-80
|
|
|
|
|
|
14) Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008; 134: 877-86
|
|
|
|
|
|
15) Ku S, Soragni E, Campau E, et al. Friedreichʼs ataxia induced pluripotent stem cells model intergenerational GAA・TTC triplet repeat instability. Cell Stem Cell. 2010; 7: 631-7
|
|
|
|
|
|
16) Liu J, Verma PJ, Evans-Galea MV, et al. Generation of induced pluripotent stem cell lines from friedreich ataxia patients. Stem Cell Rev. 2011; 7: 703-13
|
|
|
|
|
|
17) Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysauto-nomia using patient-specific iPSCs. Nature. 2009; 461: 402-6
|
|
|
|
|
|
18) Chiang CH, Su Y, Wen Z, et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry. 2011; 16: 358-60
|
|
|
|
|
|
19) Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011; 473: 221-5
|
|
|
|
|
|
20) Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010; 143: 527-39
|
|
|
|
|
|
21) Cheung AY, Horvath LM, Grafodatskaya D, et al. Isolation of MECP2-null Rett syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet. 2011; 20: 2103-15
|
|
|
|
|
|
22) Osafune K, Caron L, Borowiak M, et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol. 2008; 26: 313-5
|
|
|
|
|